High-grade glioma prognosis

• PERMA-based psychological intervention in glioma rehabilitation: An RCT on affective distress, treatment adherence, and neuro-oncological outcomes
• Systematic review and epistemic meta-analysis to advance binomial AI-radiomics integration for predicting high-grade glioma progression and enhancing patient management
• Favorable Response to Conventional Chemoradiotherapy in Radiation-induced Glioma Harboring Coamplification of PDGFRA, KIT, and KDR: A Case Report and Literature Review
• Aberrant expression of CNTRL was associated with poor prognosis, immune response and progression in glioma
• Mediation Mendelian randomization analysis of immune cell phenotypes and glioma risk: unveiling the regulation of cerebrospinal fluid metabolites
• Targeting the kynurenine pathway in gliomas: Insights into pathogenesis, therapeutic targets, and clinical advances
• Evaluating treatment outcome of Glioblastoma with Stupp's regimen: an experienced in single Institute
• Butterfly glioblastoma: trends in therapeutic modalities, extent of resection and survival in the temozolomide era. a SEER-based study

5-year survival rates of 30.9% for WHO grade III glioma and 6.6% for WHO grade IV glioma.

see Glioblastoma prognosis.

Anaplastic astrocytoma outcome

In pretreated high-grade gliomas, right hemisphere lesions are associated with reduced HRQoL scores in most functional domains except communication ability, compared to tumors of the left hemisphere. These relationships are mainly observed for T2/FLAIR lesions involving structural and functional networks in the right hemisphere. The data suggest that sparing the right hemisphere from treatment-related tissue damage may improve HRQoL in glioma patients ¹⁾

Diagnosis and treatment of high-grade glioma with leptomeningeal disease are challenging. Aggressive control of ICP followed by early initiation of standard concurrent chemoradiotherapy (CCRT) seems to help improve symptoms. However, despite aggressive treatment, the prognosis is poor. A multicenter trial and research may be necessary to create a standardized protocol for this disease ²⁾.